Saturday 17 October 2026
Export JAZZ’s income statement to Excel — free account
Jazz Pharmaceuticals PLC
JAZZ Healthcare Biotechnology
Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 126.0%, free cash flow grew 141.0% and total debt fell 18.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
210.05
4.37
−2.04%
Follow JAZZ
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(8.80%) | (8.47%) | 0.68% | 22.11% | |
Piotroski F-Score |
5 | 5 | 6 | 7 | |
| (3.03%) | (3.01%) | 0.25% | 8.54% | ||
ROIC |
(4.24%) | (3.72%) | (0.34%) | 8.06% | |
Return on Tangible Assets |
(21.41%) | (16.77%) | 1.16% | 48.26% | |
Average Days of Receivables |
67.10 | 71.05 | 68.77 | 69.88 | |
Free Cash Flow per Share |
6.28 | 5.18 | 5.07 | 22.41 | |
Free Cash Flow |
380.97 | 316.14 | 313.74 | 1,416.54 | |
Capital Expenditures |
(1,010.86) | (1,039.64) | (1,020.44) | (244.54) | |
| Other line items | |||||
Cash ROIC |
3.35% | 2.61% | 2.46% | 12.48% | |
Accounts Receivable Turnover |
5.59 | 5.52 | 5.96 | 5.77 | |
Accounts Payable Turnover |
4.03 | 5.03 | 5.44 | 4.89 | |
Inventory Turnover |
0.94 | 1.12 | 1.15 | 1.12 | |
Average Days of Payables |
116.12 | 88.55 | 68.51 | 88.01 | |
Days of Inventory on Hand |
368.52 | 302.42 | 299.72 | 303.43 | |
Tax Rate |
(0.48) | (0.43) | (1.14) | 0.29 | |
Research and Development Expense of Revenue |
19.46% | 18.34% | 17.98% | 17.73% | |
Selling, General and Administrative Expense of Revenue |
42.63% | 42.40% | 37.13% | 36.48% | |
Share Based Compensation of Revenue |
6.99% | 6.82% | 6.71% | 6.67% | |
Interest Coverage |
(2.46) | (2.21) | (0.21) | 5.25 | |
Operating CF/Net income |
(3.89) | (3.81) | 45.30 | 1.77 | |
Depreciation/Fixed assets |
3.63 | 3.48 | 3.51 | 3.39 | |
Capex/Depreciation |
(1.47) | (1.49) | (1.43) | (0.34) | |
Revenue per Share |
68.50 | 69.98 | 71.71 | 72.81 | |
Operating CF per Share |
22.93 | 22.23 | 21.55 | 26.28 | |
Capex per Share |
(16.65) | (17.05) | (16.49) | (3.87) | |
Capex to Sales |
0.24 | 0.24 | 0.23 | 0.05 |
Columns are period end dates